3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
NIH
4
OTHER
3
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Glioblastoma
94
Glioma
32
Brain Neoplasms
29
Melanoma
21
Neoplasms
17
Astrocytoma
17
Sarcoma, Ewing
7
Ovarian Neoplasms
7
Gliosarcoma
7
Carcinoma, Non-Small-Cell Lung
7
Neuroblastoma
6
Neoplasm Metastasis
6
Medulloblastoma
6
Breast Neoplasms
6
Sarcoma
5
Recurrence
5
Diffuse Intrinsic Pontine Glioma
5
Small Cell Lung Carcinoma
4
Rhabdomyosarcoma
4
Oligodendroglioma
4
Spinal Cord Neoplasms
3
Prostatic Neoplasms
3
Pancreatic Neoplasms
3
Central Nervous System Neoplasms
3
Triple Negative Breast Neoplasms
2
Rhabdoid Tumor
2
Neuroendocrine Tumors
2
Lymphoma, Follicular
2
Head and Neck Neoplasms
2
Fallopian Tube Neoplasms
2
Interventions
robatumumab
1
pegfilgrastim
1
omburtamab I-131
1
lenvatinib
1
exatecan
1
cixutumumab
1
amino-acid, glucose, and electrolyte solution
1
Temozolomide
1
Irinotecan
1
Fentanyl
1
FANG vaccine
1
Everolimus
1
177Lu-octreotide, DOTA(0)-Tyr(3)-
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Neuroectodermal Tumors, Primitive, Peripheral
×
Temozolomide
×
Clear all
NCT03495921
2023-04-26
VITA
Gradalis, Inc.
Phase 3
Terminated
32 enrolled
13 charts